Published in Proc Natl Acad Sci U S A on March 22, 2010
Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J Natl Cancer Inst (2012) 1.99
A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat Genet (2010) 1.78
Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med (2011) 1.54
A genome-wide integrative genomic study localizes genetic factors influencing antibodies against Epstein-Barr virus nuclear antigen 1 (EBNA-1). PLoS Genet (2013) 1.15
Incidence patterns and outcomes for hodgkin lymphoma patients in the United States. Adv Hematol (2010) 1.08
Viruses and human cancer: from detection to causality. Cancer Lett (2010) 1.05
A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus. Nat Commun (2014) 0.97
Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. Am J Transplant (2011) 0.91
HLA associations in classical Hodgkin lymphoma: EBV status matters. PLoS One (2012) 0.90
T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications. Adv Hematol (2010) 0.88
Evidence of genetic susceptibility to infectious mononucleosis: a twin study. Epidemiol Infect (2011) 0.88
Epstein-Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer (2016) 0.88
HLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in China. PLoS One (2012) 0.84
Carcinogenesis of nasopharyngeal carcinoma: an alternate hypothetical mechanism. Chin J Cancer (2016) 0.83
The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma. Clin Exp Immunol (2015) 0.83
Clinical, molecular, and environmental risk factors for hodgkin lymphoma. Adv Hematol (2010) 0.80
Familial predisposition and genetic risk factors for lymphoma. Blood (2015) 0.79
Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far? Clin Dev Immunol (2013) 0.79
Progress, prospects, and problems in Epstein-Barr virus vaccine development. Curr Opin Virol (2014) 0.79
Intracellular heavy metal nanoparticle storage: progressive accumulation within lymph nodes with transformation from chronic inflammation to malignancy. Int J Nanomedicine (2010) 0.78
Modeling HLA associations with EBV-positive and -negative Hodgkin lymphoma suggests distinct mechanisms in disease pathogenesis. Int J Cancer (2015) 0.78
Analysis of an ankyrin-like region in Epstein Barr Virus encoded (EBV) BZLF-1 (ZEBRA) protein: implications for interactions with NF-κB and p53. Virol J (2011) 0.76
Time correlation between mononucleosis and initial symptoms of MS. Neurol Neuroimmunol Neuroinflamm (2017) 0.75
Meta-analysis of genome-wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis. Int J Epidemiol (2016) 0.75
HLA Allele E*01:01 Is Associated with a Reduced Risk of EBV-Related Classical Hodgkin Lymphoma Independently of HLA-A*01/*02. PLoS One (2015) 0.75
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet (1991) 4.76
Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol (2007) 4.14
A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol (1999) 3.36
The biology of Hodgkin's lymphoma. Nat Rev Cancer (2008) 3.31
Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst (2005) 3.19
Model selection for extended quasi-likelihood models in small samples. Biometrics (1995) 3.01
Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med (2003) 2.81
Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer (1990) 2.28
Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomarkers Prev (1994) 2.26
Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol (2000) 2.17
HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS One (2007) 2.05
Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet (2005) 2.03
Is EBV persistence in vivo a model for B cell homeostasis? Immunity (1996) 1.94
A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis (2006) 1.64
Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res (2007) 1.45
Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. J Immunol (2005) 1.42
On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood (2007) 1.36
Epstein-Barr virus-associated Hodgkin's lymphoma. Br J Haematol (2004) 1.36
Immunobiology and pathophysiology of Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program (2005) 1.35
HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood (2007) 1.30
HLA class I polymorphisms are associated with development of infectious mononucleosis upon primary EBV infection. J Clin Invest (2007) 1.22
Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood (1996) 1.21
Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood (1998) 1.16
AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. Clin Cancer Res (2008) 1.11
The human leukocyte antigen class I region is associated with EBV-positive Hodgkin's lymphoma: HLA-A and HLA complex group 9 are putative candidate genes. Cancer Epidemiol Biomarkers Prev (2006) 1.07
Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. Br J Cancer (2000) 1.06
Childhood social environment and Hodgkin's lymphoma: new findings from a population-based case-control study. Cancer Epidemiol Biomarkers Prev (2004) 1.06
HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma. Tissue Antigens (2008) 1.06
The immune response to Epstein-Barr virus. Microbes Infect (2004) 1.04
Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Res (2001) 1.02
The Scotland and Newcastle epidemiological study of Hodgkin's disease: impact of histopathological review and EBV status on incidence estimates. J Clin Pathol (2003) 1.01
A mechanism for the HLA-A*01-associated risk for EBV+ Hodgkin lymphoma and infectious mononucleosis. Blood (2008) 0.97
Widespread sequence variation in Epstein-Barr virus nuclear antigen 1 influences the antiviral T cell response. J Infect Dis (2008) 0.96
An epidemiologic study of index and family infectious mononucleosis and adult Hodgkin's disease (HD): evidence for a specific association with EBV+ve HD in young adults. Int J Cancer (2003) 0.91
Determination of HLA-A*02 antigen status in Hodgkin's disease and analysis of an HLA-A*02-restricted epitope of the Epstein-Barr virus LMP-2 protein. Int J Cancer (1997) 0.87
Phenotype and frequency of Epstein-Barr virus-infected cells in pretreatment blood samples from patients with Hodgkin lymphoma. Br J Haematol (2005) 0.86
Exposure to childhood infections and risk of Epstein-Barr virus--defined Hodgkin's lymphoma in women. Int J Cancer (2005) 0.82
HLA class I (A, B) and II (DR, DQ) gene and haplotype frequencies in blood donors from Wales. Exp Clin Immunogenet (1998) 0.77
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2005) 16.35
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2011) 13.30
A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med (2002) 10.64
Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med (2014) 10.06
Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med (2010) 8.71
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst (2008) 8.62
Genome partitioning of genetic variation for complex traits using common SNPs. Nat Genet (2011) 8.57
Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med (2012) 7.78
Natural history of early, localized prostate cancer. JAMA (2004) 7.44
A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med (2002) 7.14
The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev (2006) 6.61
Staphylococcus aureus CC398: host adaptation and emergence of methicillin resistance in livestock. MBio (2012) 6.50
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol (2011) 5.75
Long-term colorectal-cancer mortality after adenoma removal. N Engl J Med (2014) 5.05
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Growth patterns and the risk of breast cancer in women. N Engl J Med (2004) 4.78
Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol (2005) 4.76
Non-communicable diseases in sub-Saharan Africa: what we know now. Int J Epidemiol (2011) 4.74
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73
Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet (2008) 4.70
Smoke-free legislation and hospitalizations for acute coronary syndrome. N Engl J Med (2008) 4.57
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet (2007) 4.22
The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg (2007) 4.22
Low carbohydrate-high protein diet and incidence of cardiovascular diseases in Swedish women: prospective cohort study. BMJ (2012) 4.05
Disruption of an AP-2alpha binding site in an IRF6 enhancer is associated with cleft lip. Nat Genet (2008) 4.04
Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA (2003) 4.01
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol (2012) 3.95
Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet (2007) 3.84
Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet (2002) 3.82
Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol (2009) 3.70
Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet (2012) 3.68
Effect of low doses of ionising radiation in infancy on cognitive function in adulthood: Swedish population based cohort study. BMJ (2004) 3.67
The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. Br J Gen Pract (2005) 3.65
A genome-wide association study of cleft lip with and without cleft palate identifies risk variants near MAFB and ABCA4. Nat Genet (2010) 3.63
Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity (2012) 3.58
Suicide and cardiovascular death after a cancer diagnosis. N Engl J Med (2012) 3.56
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med (2006) 3.50
Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol (2011) 3.45
The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer (2007) 3.44
Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet (2010) 3.37
Metoclopramide in pregnancy and risk of major congenital malformations and fetal death. JAMA (2013) 3.30
Association between thimerosal-containing vaccine and autism. JAMA (2003) 3.30
A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J Natl Cancer Inst (2003) 3.29
More time for complex consultations in a high-deprivation practice is associated with increased patient enablement. Br J Gen Pract (2007) 3.20
Lung cancer incidence in never smokers. J Clin Oncol (2007) 3.20
Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst (2005) 3.19
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst (2005) 3.07
Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology (2007) 3.06
Risk of cancer after blood transfusion from donors with subclinical cancer: a retrospective cohort study. Lancet (2007) 3.00
Use of macrolides in mother and child and risk of infantile hypertrophic pyloric stenosis: nationwide cohort study. BMJ (2014) 2.99
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol (2013) 2.94
Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol (2005) 2.91
Childhood vaccination and type 1 diabetes. N Engl J Med (2004) 2.89
Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol (2010) 2.86
Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial. Eur Urol (2013) 2.84
Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med (2003) 2.81
Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. J Allergy Clin Immunol (2009) 2.74
Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study. Lancet (2002) 2.72
Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. BMC Cancer (2006) 2.71
MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood (2008) 2.71
Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol (2002) 2.63
The shaping of modern human immune systems by multiregional admixture with archaic humans. Science (2011) 2.63
Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol (2012) 2.62
Genome-wide association study identifies sequence variants on 6q21 associated with age at menarche. Nat Genet (2009) 2.58
Average energy intake among pregnant women carrying a boy compared with a girl. BMJ (2003) 2.55
A high-density screen for linkage in multiple sclerosis. Am J Hum Genet (2005) 2.50
Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst (2007) 2.49
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol (2008) 2.46
Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst (2002) 2.44
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg (2012) 2.43
Relevance and practical use of the Consultation and Relational Empathy (CARE) Measure in general practice. Fam Pract (2005) 2.41
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol (2011) 2.38
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
Sector resection with or without postoperative radiotherapy for stage I breast cancer: 20-year results of a randomized trial. J Clin Oncol (2014) 2.35
Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol (2002) 2.28
Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol (2012) 2.28
Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis. Lancet Oncol (2005) 2.27
Evidence-based medicine: the time has come to set standards for staging. J Pathol (2010) 2.26
Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst (2006) 2.23